---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-007863"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:05:28.993195+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Arbutus Biopharma appoints Tram Tran, M.D. to board of directors

## Summary
- Board expanded to nine members; Dr. Tran appointed effective November 9, 2021.
- Annual cash retainer of $40,000 plus option for 44,000 shares at $3.50, vesting over 3 years.
- Dr. Tran is CMO at Glympse and former Gilead VP, with expertise in liver diseases and HBV.
- Appointment runs until the 2022 annual general meeting, subject to continued board service.

## SEC filing metadata
- accession: 0001171843-21-007863
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184321007863/0001171843-21-007863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184321007863/f8k_111121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-007863
- JSON: https://secwatch.observer/filing/0001171843-21-007863.json
- Plain text: https://secwatch.observer/filing/0001171843-21-007863.txt

## Key facts
- Executive change
  Tram Tran was appointed as Director at Arbutus Biopharma Corp.
  - Action: appointed
  - Role: Director
  source text: On November 9, 2021, the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) (a) increased the size of the Board by one member such that the Board will thereafter consist of nine directors and (b) appointed Tram Tran, M.D. to the Board, to serve until the Company’s 2022 annual general meeting of shareholders and until her successor is duly appointed and qualified, or until her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184321007863/0001171843-21-007863-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.